Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.38 |
| ▸ | HTR2A | P28223 | 7/20 | 0.38 |
| ▸ | HTR2B | P41595 | 7/20 | 0.38 |
| ▸ | HTR1A | P08908 | 6/20 | 0.38 |
| ▸ | HTR1D | P28221 | 5/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546117 | 0.90 | MAOA (0.46) | HTR2CHTR2AHTR2BMAOAMAOB | |
| SCHEMBL13035776 | 0.80 | HTR2C (0.43) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL1143507 | 0.79 | HTR2C (0.45) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL19810478 | 0.77 | HTR2C (0.38) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL14405274 | 0.77 | HTR2C (0.38) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL13861841 | 0.77 | HTR2C (0.38) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL21500751 | 0.75 | SMN1; SMN2 (0.32) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL20778163 | 0.75 | ALDH1A1 (0.37) | MAOAMAOBMAP3K14 | |
| SCHEMBL21872053 | 0.74 | HTR2C (0.40) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL21872027 | 0.74 | HTR2C (0.43) | HTR2CHTR2AHTR2BHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220046-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-6833380-B2 | Thiazole or oxazole derivatives such as (4-(4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl)-5-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid | WARNER-LAMBERT COMPANY, LLC | 2004-12-21 | — | — | US | disclosed |
| EP-1485091-A1 | THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY | Warner-Lambert Company LLC (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030207916-A1 | Thiazole or oxazole derivatives such as (4-(4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl)-5-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074052-A1 | THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207916-A1 | Thiazole or oxazole derivatives such as (4-(4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl)-5-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid | PPARA, PPARD, PPARG | HTR2C 2627/4885HTR2A 3243/4885HTR2B 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.